Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06336863
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-07-05
First Post:
2024-03-21
Brief Title:
Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
An Extension Protocol for Subjects Previously Enrolled in the Use of Donor Derived-cell Free DNA AlloSure and Gene Expression Profiling AlloMap Kidney to Facilitate Belatacept Monotherapy in Kidney Transplant Patients
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to provide immunosuppression weaning andor monitoring for an additional 12-months to evaluate the safety and efficacy of belatacept monotherapy in patients previously enrolled in the clinical trial Use of donor derived-cell free DNA AlloSure and gene expression profiling AlloMap Kidney to facilitate Belatacept monotherapy in kidney transplant patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None